Summit Therapeutics (SMMT) Common Equity (2018 - 2026)

Summit Therapeutics (SMMT) has reported Common Equity for 9 consecutive years, with $630.0 million the latest figure, recorded in Q2 2026.

• Quarterly Common Equity rose 142.83% year-over-year to $630.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $630.0 million (up 142.83% YoY) and the FY2025 annual result came in at $658.9 million, up 69.48% from the prior year.
• Common Equity grew to $630.0 million in Q2 2026 per SMMT's latest filing, from $545.9 million in the prior quarter.
• Over the last five years, Common Equity for SMMT reached as high as $658.9 million in Q4 2025 and fell as low as $44.2 million in Q1 2024.
• A 5-year average of $250.1 million and a median of $162.9 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity sank 66.88% — and 2025, when it surged 678.85%.
• Year by year, Common Equity stood at $126.7 million in 2022, then plunged by 38.66% to $77.7 million in 2023, then jumped by 400.37% to $388.7 million in 2024, then soared by 69.48% to $658.9 million in 2025, then decreased by 4.38% to $630.0 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $630.0 million, $545.9 million, and $658.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.